Admin Posted December 15, 2017 Share Posted December 15, 2017 There are two committees that recommend public expenditure on medical treatments in Australia - the Medical Services Advisory Committee (MSAC) and the Pharmaceutical Benefits Advisory Committee (PBAC). The MSAC approved the use of Xofigo for prostate cancer patients in 2014. The PBAC announced approval of Xofigo for prostate cancer patients today (15 December 2017). The delays were due in part to this being the first treatment that needs to be paid for by both Medicare and the PBS. New rules had to be made. Ministerial approval can be expected in the near future, and men who need this treatment for prostate cancer in the bones will be able to get it. Many of our members sent submissions to both the MSAC and the PBAC, and I am convinced that had a big part to play in the result. Members should know that although I fronted this campaign, speaking to parliamentary lunches, and to public meetings and parliamentarians in marginal electorates, and making the videos, all Executive Committee members contributed to the campaign, and that one, the late Paul Hobson, was the real driving force behind this result. Thanks go to all who contributed. Jim Marshall Convenor Australian Advanced Prostate Cancer Support Group Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.